Ainos (NASDAQ:AIMD) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) Head-To-Head Contrast

Ainos (NASDAQ:AIMD) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares Ainos and NeuroBo Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$122,112.00	51.32	-$13.77 million	($2.55)	-0.40
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A

NeuroBo Pharmaceuticals has lower revenue, but higher earnings than Ainos.

Institutional and Insider Ownership

1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 4.6% of Ainos shares are owned by insiders. Comparatively, 0.8% of NeuroBo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Ainos and NeuroBo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-11,205.49%	-47.96%	-40.37%
NeuroBo Pharmaceuticals	N/A	-59.42%	-45.40%

Volatility and Risk

Ainos has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Ainos and NeuroBo Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
NeuroBo Pharmaceuticals	0	0	0	0	N/A

Summary

Ainos beats NeuroBo Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.